astellas osi pharma新闻稿泰来制药将收购inc.pdfVIP

Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc. Companies enter into definitive merger agreement to combine to create a world- class oncology platform OSI Stockholders to receive $57.50 per share in cash Tokyo, Japan, and Melville, N.Y. – May 16, 2010 – Astellas Pharma Inc. (TSE: 4503), a global pharmaceutical company, and OSI Pharmaceuticals, Inc. (Nasdaq: OSIP), a biotechnology company primarily focused on the discovery, development and commercialization of molecular targeted therapies addressing medical needs